予果生物, founded in February 2017, focuses on translating cell-free metagenomic NGS (mNGS) into clinical diagnostics and developing proprietary algorithms. The company says it has built the largest bioinformatics team in the industry and its core R&D staff have deep gene-sequencing experience, including participation in the Human Microbiome Project and over 600 cumulative impact-factor points from publications in the past decade. In 2020 the company collaborated with Dennis Kasper and published as first author in PNAS, cited in the article as the highest-level domestic mNGS infection and immunity paper. Commercially, 予果生物 has established a large marketing and medical-support system to support clinical services and market education. Financially, it has completed six rounds of equity financing and reports its cumulative financing remains among the industry's highest; it just closed a new RMB 200 million round. Investors and partners quoted in the article express expectations that the company can grow into a global platform covering microbial-detection services.

Total raised

$32M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020